2019 About APS EB 2019 Information

SGLT2 Inhibitors: From Basic Physiology to Clinical Success

Symposium — Sunday, April 7, 2019 — 1:30 PM - 3:00 PM — Convention Center, Room W311B
Physiologists in Industry Committee — Chair: Romer Gonzalez Villalobos — Co-Chair: Paramita Pati
Cosponsored by AJP - Renal Physiology

Basic physiology experiments indicate that the sodium-glucose cotransporter 2 (SGLT2) is responsible for most glucose reabsorption in the kidneys, a key mechanism for glucose homeostasis.  Based on this knowledge, SGLT2 inhibitors (SGLT2i) were developed to lower plasma glucose in diabetic patients.  However, in addition to its glucose lowering effects, several large clinical trials showed that SGLT2i confer strong cardiovascular and possibly renal protection.  These findings resulted in a multiplicity of ongoing efforts looking to expand the use of SGLT2i to other indications including heart failure and diabetic kidney disease.  These observations make the SGLT2i an excellent example of the broad impact that the study of physiology continues to have in human medicine. 


  • The Basic Physiological Mechanisms of SGLT2 Inhibition
    Scott Thompson — Div. of Nephrology-Hypertension, UCSD Sch. of Med.

  • Empagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
    Maximilian von Eynatten — TA Metabolism Medicine, Boehringer INgelheim International GmbH

  • Canagliflozin and Renal Outcomes in Type 2 Diabetes
    Jennifer Davidson — Vice-President, Global medical Affairs Cardiovascular and Metabolism, Janssen Pharmaceuticals

Host Societies

Experimental Biology is the annual meeting of five Host Societies. By becoming a member of one of the societies below before registering, you can save up to $200 off the price of regular registration. Click a Host Society logo below to join today and save:

Copyright © Experimental Biology (EB) | Experimental Biology® is a federally registered trademark of EB.